Literature DB >> 25547719

5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy.

Marcel A Kamp1, Jörg Felsberg, Hosai Sadat, Jamshid Kuzibaev, Hans-Jakob Steiger, Marion Rapp, Guido Reifenberger, Maxiné Dibué, Michael Sabel.   

Abstract

BACKGROUND: The 5-aminolevulinic acid (5-ALA) fluorescence-guided resection of recurrent malignant glioma is a standard surgical procedure at many neuro-oncological centers and is considered to be equally reliable as the primary resection of these tumors. 5-ALA induced fluorescence (5-AIF)-guided resection has been demonstrated to be highly predictive for tumor tissue. As pseudoprogression and radiation-induced necrosis are critical differential diagnoses of glioma recurrence, the purpose of the present analysis was to analyze 5-AIF behavior in resected tissue specimens histopathologically showing regressive and reactive changes but lacking active, that is, cellular recurrent tumor tissue after adjuvant treatment of malignant glioma.
METHODS: A retrospective analysis was performed in patients suffering from malignant glioma who underwent surgical resection for suspected contrast-enhancing tumor recurrence (according to RANO criteria) at our institution between 2007 and 2013, but in whom histopathological analysis only revealed reactive changes. The presence of AIF in the resected tissue samples was intraoperatively assessed and classified by the surgeon, using the categories (1) no, (2) vague and (3) solid AIF.
RESULTS: A total of 13 out of 313 patients who underwent AIF-guided surgical resection of tissue suspicious for recurrent glioma histologically demonstrated only reactive changes without active recurrent tumor tissue after adjuvant therapy. Pretreatment was chemotherapy with temozolomide in 1 patient and combined radio-/chemotherapy in 12 patients. Six patients had suffered previous tumor recurrence with a subsequently intensified adjuvant therapy. Seven of the 13 patients displayed solid, 5 patients vague and 1 patient no 5-AIF of the resected tissue specimens. However, all 5-AIF-positive lesions exhibited heterogeneous fluorescence patterns with vaguely or solidly fluorescent as well as nonfluorescent regions.
CONCLUSIONS: Resection of reactive tissue without active recurrent tumor after multimodal treatment for glioblastoma is frequently associated with solid or vague 5-AIF. Therefore, neurosurgeons should remain cautious when attempting to employ intraoperative 5-AIF to discriminate radiation- and chemotherapy-induced tissue changes from true disease progression. Nevertheless, 5-AIF-guided resection remains a valid tool in the neurosurgical treatment of recurrent gliomas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25547719     DOI: 10.1007/s00701-014-2313-4

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  16 in total

Review 1.  The impact of cerebral metastases growth pattern on neurosurgical treatment.

Authors:  Marcel A Kamp; Philipp J Slotty; Jan F Cornelius; Hans-Jakob Steiger; Marion Rapp; Michael Sabel
Journal:  Neurosurg Rev       Date:  2016-07-09       Impact factor: 3.042

Review 2.  Fluorescent-Guided Surgical Resection of Glioma with Targeted Molecular Imaging Agents: A Literature Review.

Authors:  Sonya E L Craig; James Wright; Andrew E Sloan; Susann M Brady-Kalnay
Journal:  World Neurosurg       Date:  2016-02-23       Impact factor: 2.104

3.  5-Aminolevulinic Acid-Induced Fluorescence in Focal Cortical Dysplasia: Report of 3 Cases.

Authors:  David W Roberts; Jaime J Bravo; Jonathan D Olson; William F Hickey; Brent T Harris; Lananh N Nguyen; Jennifer Hong; Linton T Evans; Xiaoyao Fan; Dennis Wirth; Brian C Wilson; Keith D Paulsen
Journal:  Oper Neurosurg (Hagerstown)       Date:  2019-04-01       Impact factor: 2.703

4.  The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas.

Authors:  Georg Widhalm; Jonathan Olson; Jonathan Weller; Jaime Bravo; Seunggu J Han; Joanna Phillips; Shawn L Hervey-Jumper; Susan M Chang; David W Roberts; Mitchel S Berger
Journal:  J Neurosurg       Date:  2019-05-10       Impact factor: 5.115

Review 5.  5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence Imaging for Tumor Detection: Recent Advances and Challenges.

Authors:  Yoshinori Harada; Yasutoshi Murayama; Tetsuro Takamatsu; Eigo Otsuji; Hideo Tanaka
Journal:  Int J Mol Sci       Date:  2022-06-09       Impact factor: 6.208

Review 6.  What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

Authors:  Costas G Hadjipanayis; Georg Widhalm; Walter Stummer
Journal:  Neurosurgery       Date:  2015-11       Impact factor: 4.654

Review 7.  Various shades of red-a systematic analysis of qualitative estimation of ALA-derived fluorescence in neurosurgery.

Authors:  Marcel A Kamp; Zarela Krause Molle; Christopher Munoz-Bendix; Marion Rapp; Michael Sabel; Hans-Jakob Steiger; Jan F Cornelius
Journal:  Neurosurg Rev       Date:  2016-05-25       Impact factor: 3.042

Review 8.  Real-Time Imaging of Brain Tumor for Image-Guided Surgery.

Authors:  Shuang Hu; Homan Kang; Yoonji Baek; Georges El Fakhri; Anren Kuang; Hak Soo Choi
Journal:  Adv Healthc Mater       Date:  2018-05-02       Impact factor: 9.933

9.  The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.

Authors:  Mohammed Jaber; Johannes Wölfer; Christian Ewelt; Markus Holling; Martin Hasselblatt; Thomas Niederstadt; Tarek Zoubi; Matthias Weckesser; Walter Stummer
Journal:  Neurosurgery       Date:  2016-03       Impact factor: 4.654

Review 10.  Clinical utility of 5-aminolevulinic acid HCl to better visualize and more completely remove gliomas.

Authors:  Sameer H Halani; D Cory Adamson
Journal:  Onco Targets Ther       Date:  2016-09-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.